UK Community Advisory Board (UK-CAB)

UKCAB 46: HIV Malignancies


09.30 – 09.50 Registration, refreshments and expenses
09.50 – 10.00 Welcome, introductions, UKCAB updates
10.00 – 11.00  CROI feedback
11.00 – 11.30 Merck Sharp & Dohme (MSD) pre-meeting
11.30 –12.15 Introduction to HIV and cancer  –  Simon Collins
12.15 –13.30 Lunch – Strada restaurant
13.30 –15.00 HIV and cancer – monitoring, screening and treatment  –  Prof. Mark Bower, National Centre for HIV Malignancy, Chelsea & Westminster Hospital
15.00 – 15.30 Break
15.30 –17.00 Company meeting: Merck Sharp & Dohme (MSD)
17.00 Meeting close

Presentations from meeting:

Introduction to HIV and cancer

HIV and cancer – Prof Mark Bower
Due to the size of the presentations, they have been split into three sections:

Part 1 of 3 –  – see additional files for parts 2 and 3.

Pre-meeting videos:

For those attending the meeting – please take time to watch the following videos – about half an hour each in preparation for Friday’ s meeting.  Prof Mark Bower is the main speaker; here is his last BHIVA webcast:

Do cancer patients with HIV die sooner? – Professor Mark Bower, Chelsea and Westminster Hospital, London.

Best of CROI 2013 feedback from London – the following videos are useful:

Co-infections, opportunistic infections and malignancies  – Dr Sanjay Bhagani, Royal Free Hospital, London

HIV transmission, prevention and testing  – Professor Martin Fisher, Royal Sussex County Hospital, Brighton

Amy Justice at CROI on HIV and ageing – video has some slides on the risks of cancers in HIV positive people

Background Reading:

HIV and cancer

Cancers in people with HIV: who gets them, and which ones?

Issues that divide expert opinion: when to start, HIV and ageing and the impact of HIV on life expectancy

KS in the HAART era includes patients with high CD4 and suppressed viral load: importance of KS chemotherapy for some patients in addition to ART

T-cell senescence linked to KS in people with good HIV control

HIV infection and cancer risk

Financial support

The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.

The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.

We believe that manufacturers who currently develop and market medicines have a responsibility to actively engage with advocacy organisations and that HIV positive people and their advocates should be able to directly question manufacturers about the safety and efficacy of their products and proposals for future research.

For a list of companies that support the UK-CAB please see the “about us” page.